We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Critical immunotherapy target marks dysfunctional regulatory T cells in brain cancer

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Critical immunotherapy target marks dysfunctional regulatory T cells in brain cancer "

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Immunotherapy represents an exciting advance in cancer treatment that harnesses the immune system to seek and destroy cancer cells.

The programmed death 1 (PD-1) pathway dampens immune responses to tumor cells, and several clinical trials have shown favorable outcomes by targeting PD-1 or its ligand PD-1L.

See Also: New combination treatment strategy to 'checkmate' glioblastoma

In JCI Insight, David Hafler and colleagues at Yale University and Massachusetts Institute of Technology examined PD-1-expressing regulatory T cells in glioblastoma multiforme, an extremely aggressive form of brain cancer.

Regulatory T cells normally constrain immune responses and keep other types of T cells from mounting hyper-aggressive responses.

Although anti-PD1 therapy is generally thought to promote conventional T cell activity, the Hafler team now reports that PD-1 expression on regulatory T cells from the tumors of glioblastoma multiforme patients correlates with regulatory T cell dysfunction.

They also found that glioblastoma multiforme patients treated with a PD-1 blocking antibody had a higher proportion of dysfunctional regulatory T cells.

Related: Less is more: Modified poliovirus therapy for glioblastoma

These observations suggest the possibility that PD-1 targeting therapies could work, in part, by driving further regulatory T cell dysfunction.

Future studies will be needed to more fully understand the contribution of this pathway to anti-tumor effects.

Note: Material may have been edited for length and content. For further information, please contact the cited source.

Journal of Clinical Investigation


Lowther DE et al. PD-1 marks dysfunctional regulatory T cells in malignant gliomas.   JCI Insight, Published April 21 2016. doi: 10.1172/jci.insight.85935